

# JASN<sup>®</sup>

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

September 2022 • Vol. 33 • No. 9

## **This Month's Highlights**

### **UP FRONT MATTERS**

#### **Editorials**

**1629 Decorating Histones in Polycystic Kidney Disease**

Harini Ramalingam and Vishal Patel

- See related article by Dang et al. (pp. 1708–1725).

**1631 ★Complement is Complimentary in Membranous Nephropathy**

Ralph Kettritz and Adrian Schreiber

- See related article by Gao et al. (pp. 1742–1756).

**1633 ★Searching for the Risk-Benefit Profile of Higher Potassium Intake in CKD: *Primum Non Nocere***

Murilo Guedes and Roberto Pecoits-Filho

- See related article by Gritter et al. (pp. 1779–1789).

**1635 ★Assessing the Carbon Footprint of Hemodialysis: A First Step Toward Environmentally Sustainable Kidney Care**

Katherine A. Barraclough and Scott McAlister

- See related article by Sehgal et al. (pp. 1790–1795).

#### **Perspective**

**1638 ★The Highs and Lows of Potassium Intake in CKD—Does One Size Fit All?**

Andrew S. Terker, Turgay Saritas, and

Alicia A. McDonough

- See related article by Gritter et al. (pp. 1779–1789).

#### **Review**

**1641 Emerging Insights into Glomerular Vascular Pole and Microcirculation**

Michael S. Goligorsky

### **SPECIAL SERIES ON ADDRESSING RACIAL AND ETHNIC DISPARITIES IN KIDNEY DISEASE**

**1649 The Potential for Pragmatic Trials to Reduce Racial and Ethnic Disparities in Kidney Disease**

Laura M. Dember

**1652 Health Care Equity and Justice Scorecard To Increase Diversity in Clinical Trial Recruitment and Retention**

Susanne B. Nicholas and Lilia Cervantes, on behalf of the Clinical Care & Innovation Workgroup of the American Society of Nephrology Health Care Justice Committee

### **META-ANALYSIS**

#### **Chronic Kidney Disease**

**1657 Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes**

Caroline Liu, Neha Debnath, Gohar Mosoyan, Kinsuk Chauhan, George Vasquez-Rios, Celine Soudant, Steve Menez, Chirag R. Parikh, and Steven G. Coca

### **RESEARCH LETTER**

#### **Genetic Disease of the Kidney**

**1673 Cation Channel Activity of Apolipoprotein L1 is Modulated by Haplotype Background**

Rebecca L. Winkler, Jonathan Bruno, Paula Buchanan, and John C. Edwards

### **BASIC RESEARCH**

#### **Chronic Kidney Disease**

**1677 Kidney Failure Alters Parathyroid Pin1 Phosphorylation and Parathyroid Hormone mRNA-Binding Proteins, Leading to Secondary Hyperparathyroidism**

Alia Hassan, Yael E. Pollak, Rachel Kilav-Levin, Justin Silver, Nir London, Morris Nechama, Iddo Z. Ben-Dov, and Tally Naveh-Many

#### **Development of the Kidney**

**1694 Transcription Factors YAP/TAZ and SRF Cooperate To Specify Renal Myofibroblasts in the Developing Mouse Kidney**

Keri A. Drake, Christopher Chaney, Mohita Patel, Amrita Das, Julia Bittencourt, Martin Cohn, and Thomas J. Carroll

### **Genetic Disease of the Kidney**

#### **1708 Nuclear Condensation of CDYL Links Histone Crotonylation and Cystogenesis in Autosomal Dominant Polycystic Kidney Disease**

Lin Dang, Xinyi Cao, Tianye Zhang, Yongzhan Sun, Shanshan Tian, Tianyu Gong, Hui Xiong, Peipei Cao, Yuhao Li, Shengqiang Yu, Li Yang, Lirong Zhang, Tong Liu, Kai Zhang, Jing Liang, and Yupeng Chen

• See related editorial by Ramalingam and Patel (pp. 1629–1630).

#### **1726 KLC3 Regulates Ciliary Trafficking and Cyst Progression in CILK1 Deficiency–Related Polycystic Kidney Disease**

Gyueong Rah, Hwayeon Cha, Joohee Kim, Jieun Song, Hyunho Kim, Yun Kyu Oh, Curie Ahn, Minyong Kang, Jongmin Kim, Kyung Hyun Yoo, Min Jung Kim, Hyuk Wan Ko, Je Yeong Ko, and Jong Hoon Park

### **Glomerulonephritis and Interstitial Nephritis**

#### **1742 ★Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy**

Shuang Gao, Zhao Cui, and Ming-hui Zhao

• See related editorial by Kettritzon and Schreiber (pp. 1631–1633).

### **CLINICAL EPIDEMIOLOGY**

#### **Chronic Kidney Disease**

#### **1757 ★Hurricanes and Mortality among Patients Receiving Dialysis**

Matthew F. Blum, Yijing Feng, G. Brooke Anderson, Dorry L. Segev, Mara McAdams-DeMarco, and Morgan E. Grams

#### **Pharmacology and Therapeutic Development**

#### **1767 Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria**

Jung-Im Shin, Derek M. Fine, Yingying Sang, Aditya Surapaneni, Stephan C. Dunning, Lesley A. Inker, Thomas D. Nolin, Alex R. Chang, and Morgan E. Grams

### **CLINICAL RESEARCH**

#### **Chronic Kidney Disease**

#### **1779 ★Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD**

Martin Gritter, Rosa D. Wouda, Stanley M.H. Yeung, Michiel L.A. Wieërs, Frank Geurts, Maria A.J. de Ridder, Christian R.B. Ramakers, Liffert Vogt, Martin H. de Borst, Joris I. Rotmans, and Ewout J. Hoorn, on behalf of K<sup>+</sup> onsortium

• See related editorial by Guedes and Pecoits-Filho (pp. 1633–1634) and perspective by Terker (pp. 1638–1640)

### **Dialysis**

#### **1790 ★Sources of Variation in the Carbon Footprint of Hemodialysis Treatment**

Ashwini R. Sehgal, Jonathan E. Slutzman, and Anne M. Huml

• See related editorial by Barraclough and McAlister (pp. 1635–1637).

### **LETTERS TO THE EDITOR**

#### **1797 The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo**

Paul T. Conway, Nieltje Gedney, Shuvo Roy, and William H. Fissell

• See related reply, Authors' Reply: "The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo" and "The Advancing American Kidney Health Initiative: Do Not Let 80% Distract Us from the Fact that We Can Do Better" on pages 1800–1801, and original article, "The Advancing American Kidney Health Initiative: The Challenge of Measuring Success" in Vol. 33, Iss. 6, on pages 1060–1062.

#### **1798 The Advancing American Kidney Health Initiative: Do Not Let 80% Distract Us from the Fact that We Can Do Better**

Mallika L. Mendu, Scott D. Bieber, Suzanne G. Watnick, and Daniel E. Weiner

• See related reply, Authors' Reply: "The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo" and "The Advancing American Kidney Health Initiative: Do Not Let 80% Distract Us from the Fact that We Can Do Better" on pages 1800–1801, and original article, "The Advancing American Kidney Health Initiative: The Challenge of Measuring Success" in Vol. 33, Iss. 6, on pages 1060–1062.

#### **1800 Authors' Reply: "The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo" and "The Advancing American Kidney Health Initiative: Do Not Let 80% Distract Us from the Fact that We Can Do Better"**

Robert R. Quinn, Ngan N. Lam, Pietro Ravani,

Matthew J. Oliver, Peter G. Blake, and Marcello Tonelli

See related letters to the editor, "The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo" and "The Advancing American Kidney Health Initiative: Do Not Let 80% Distract Us from the Fact that We Can Do Better," on pages 1798–1799, and original article "The Advancing American Kidney Health Initiative: The Challenge of Measuring Success" in Vol. 33, Iss. 6, on pages 1060–1062.